Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The diagnosis and risk-stratification of patients with MDS has moved forward in recent years
to include the identification of several genomic targets1
Rena Buckstein, MD, FRCPC
Sunnybrook Research Institute, Toronto, Canada
Thomas Cluzeau, MD, PhD
Central University Hospital of Nice, Nice, France
Sanam Loghavi, MD
MD Anderson Cancer Center, Houston, TX
Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX
Amer Zeidan, Jan Bewersdorf, Maximilian Stahl, Yasmin Abaza, and Yazan Madanat
Eva Hellström-Lindberg, MD, PhD
Karolinska University Hospital, Stockholm, Sweden
Amer Zeidan, MBBS
Yale Cancer Center, New Haven, CT
Aditi Shastri, MD
Montefiore Medical Center, Bronx, NY
Valeria Santini, MD
University of Florence, Florence, Italy
David Sallman, MD
Moffitt Cancer Center, Tampa, FL
Uwe Platzbecker, MD
University of Leipzig, Leipzig, Germany
Jeffrey Lancet, MD
Moffitt Cancer Center, Tampa, FL
Valeria Santini, MD
University of Florence, Florence, Italy
Amer Zeidan, MBBS
Yale Cancer Center, New Haven, CT
See ClinicalTrials.gov for the latest information on the Phase III COMMANDS and IMerge trials in LR-MDS
Sources
Glossary
ESA, erythropoietin-stimulating agent; ICC, International Consensus Classification; LR, lower risk; MDS, myelodysplastic syndromes; WHO, World Health Organization
This educational activity has received independent medical education support from
Bristol Myers Squibb. This supporter has no influence over the production of the content.